Norgine Ventures B.V., founded in 2012 as a subsidiary of the European specialty pharmaceutical company Norgine. See contact routes.
Norgine Ventures B.V., founded in 2012 as a subsidiary of the European specialty pharmaceutical company Norgine, provides debt and debt-like financing to healthcare startups rather than traditional equity venture capital. The firm targets innovative, high-growth ventures in life sciences, specifically focusing on specialty pharma, diagnostic, and medical device companies across Europe and the United States. Its investment checks typically range from €5 million to €20 million, with a concentration on companies headquartered in Western Europe, though it also evaluates opportunities in Israel and the Nordic region. Norgine Ventures leverages its parent company’s technical and regulatory infrastructure to offer hybrid capital instruments that support growth without diluting equity. Notable portfolio companies include Lunaphore, which received a $54.4M debt financing in March 2023, as well as PathoQuest, Caresyntax, and SpineGuard. The firm distinguishes itself by aiming for financial returns while utilizing Norgine’s century-old operational expertise to evaluate opportunities, bridging funding gaps for growing healthcare entities with flexible financing mo
Every field above is read from the StartupFundraising firm directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with comparable investors when building a target list.
Investors like Norgine Ventures · Full investor directory · Investor access · Company funding database